Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3834334 | 0.96 | HDAC1 (0.43) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL1496885 | 0.94 | HDAC1 (0.34) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL3835238 | 0.92 | HDAC1 (0.35) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL3227901 | 0.91 | ROCK1 (0.34) | HDAC1HDAC6ROCK1ROCK2 | |
| SCHEMBL4396605 | 0.91 | HDAC1 (0.37) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL3232709 | 0.91 | HDAC1 (0.35) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL3830936 | 0.90 | HDAC1 (0.38) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL3832864 | 0.90 | HDAC1 (0.37) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL3835728 | 0.89 | KDM1A (0.36) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL3830690 | 0.89 | CASR (0.39) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076332-B2 | N- (2-aminophenyl) benzamide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2107052-A1 | NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2009-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | UACA, SLC14A1, ARG2 | HDAC1 200/4885HDAC6 363/4885HDAC3 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.